Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France (SYMBIOSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00812357
Recruitment Status : Completed
First Posted : December 22, 2008
Last Update Posted : December 29, 2011
Information provided by (Responsible Party):

Brief Summary:
Descriptive pharmacoepidemiological study on the use of Symbicort Turbuhaler in the treatment of asthma in France and impact of a new therapeutic strategy on the compliance and control of asthma

Condition or disease

Study Type : Observational
Actual Enrollment : 579 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Descriptive Pharmacoepidemiological Study on the Use of Symbicort Turbuhaler in the Treatment of Asthma in France and Impact of a New Therapeutic Strategy on the Compliance and Control of Asthma
Study Start Date : April 2009
Actual Primary Completion Date : March 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Patients treated with Symbicort basic treatment
Patients treated with Symbicort basic treatment + treatment of symptoms as needed

Primary Outcome Measures :
  1. Level of control of the asthma [ Time Frame: 3 months ]
  2. Evaluation of compliance with treatment [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Community sample

Inclusion Criteria:

  • Asthmatic patients treated for this disease with Symbicort Turbuhaler
  • Patients monitored for asthma by the doctor for at least 12 months
  • Patients seen in outpatient care at the baseline visit
  • Patients agreeing to participate in the study

Exclusion Criteria:

  • Patients with any chronic lower respiratory disease other than asthma
  • Patients receiving anti-IgE agents in the last 4 months
  • Patients receiving desensitisation treatment outside of the maintenance phase
  • Patients deemed to be unable to respond to the study for linguistic or cognitive reasons

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00812357

  Show 175 Study Locations
Sponsors and Collaborators
Principal Investigator: Stephane SCHÜCK, MD, MSc KAPPA SANTE - Paris - France
Study Chair: Michel AUBIER, MD, Professor CHU Bichat - Service de pneumologie - Paris - France

Responsible Party: AstraZeneca Identifier: NCT00812357     History of Changes
Other Study ID Numbers: NIS-RFR-SYM-2008/1
First Posted: December 22, 2008    Key Record Dates
Last Update Posted: December 29, 2011
Last Verified: December 2011

Keywords provided by AstraZeneca:
Symbicort Turbuhaler
cohort study

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents